

**Supplemental Table 2 Comparison of tumour burden in *Tsc2*<sup>+/-</sup> mice by histological analysis**

(Wilcoxon rank-sum test)

## A. Lesion number (all lesions)

Treatment*	Number of mice	Median	Range	Z (P) (compared with Vehicle)	Z (P) (compared with Everolimus+Sorafenib)
Vehicle	10	60.0	36 - 69		
Everolimus	10	28.5	21 - 53	3.33 (0.001)	0.49(0.600)
Sorafenib	10	53.5	28 - 73	1.14 (0.260)	2.88 (0.004)
Everolimus + Sorafenib	7	28.0	14 - 40	3.32 (0.001)	

## B. Lesion size (all lesions)

Treatment*	Number of mice	Median (mm <sup>2</sup> )	Range (mm <sup>2</sup> )	Z (P) (compared with Vehicle)	Z (P) (compared with Everolimus+Sorafenib)
Vehicle	10	26.820	14.552 - 56.238		
Everolimus	10	14.095	3.629 - 30.352	3.10 (0.002)	1.37 (0.170)
Sorafenib	10	21.854	7.209 - 46.884	0.83 (0.410)	2.64 (0.008)
Everolimus + Sorafenib	7	10.215	2.898 - 14.932	3.32 (0.001)	

## C. Lesion cellular area (all lesions)

Treatment*	Number of mice	Median (mm <sup>2</sup> )	Range (mm <sup>2</sup> )	Z (P) (compared with Vehicle)	Z (P) (compared with Everolimus+Sorafenib)
Vehicle	10	11.410	5.512 - 42.884		
Everolimus	10	1.984	0.845 - 24.254	3.10 (0.002)	1.46 (0.140)
Sorafenib	10	8.537	2.112 - 20.408	1.06 (0.290)	3.22 (0.001)
Everolimus + Sorafenib	7	1.348	0.583 - 2.382	3.42 (0.001)	

\* Treatment was started from 11 month old and continued for two months.